Skip to main content
Erschienen in: Supportive Care in Cancer 6/2018

23.12.2017 | Original Article

Digestive toxicities after palliative three-dimensional conformal radiation therapy (3D-CRT) for cervico-thoracic spinal metastases

verfasst von: Guillaume Peyraga, Delphine Caron, Thibaut Lizee, Yann Metayer, Anne-Lise Septans, Yoann Pointreau, Fabrice Denis, Gerard Ganem, Cedrik Lafond, Sophie Roche, Olivier Dupuis

Erschienen in: Supportive Care in Cancer | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Objective

The palliative treatment for cervico-thoracic spinal metastases is based on a three-dimensional conformal radiation therapy (3D-CRT). Digestive toxicities are common and cause a clinical impact frequently underestimated in patients. We performed a retrospective study of digestive side effects occurring after palliative 3D-CRT for cervico-thoracic spinal metastases.

Patients and methods

All patients receiving palliative 3D-CRT at Jean Bernard Center from January 2013 to December 2014 for spinal metastases between the 5th cervical vertebra (C5) and the 12th thoracic vertebra (T12) were eligible. Three-dimensional conformal RT was delivered by a linear accelerator (CLINAC, Varian). Premedication to prevent digestive toxicities was not used. Adverse events (“esophagitis” and “nausea and/or vomiting”) were evaluated according to the NCI-CTCae (version 4).

Results

From January 2013 to December 2014, 128 patients met the study criteria. The median age was 68.6 years [31.8; 88.6]. Most patients (84.4%) received 30 Gy in 10 fractions. The median overall time of treatment was 13 days [3–33]. Forty patients (31.3%) suffered from grade ≥ 2 of “esophagitis” (35 grade 2 (27.4%) and 5 grade 3 (3.9%)). Eight patients (6.3%) suffered from grade ≥ 2 of “nausea and/or vomiting” (6 grade 2 (4.7%), 1 grade 3 (0.8%), and 1 grade 4 (0.8%)).

Conclusion

The high incidence of moderate to severe digestive toxicities after palliative 3D-CRT for cervico-thoracic spinal metastases led to consider static or dynamic intensity-modulated radiation therapy (IMRT) to reduce the dose to organ at risk (the esophagus and stomach). Dosimetric studies and implementation in the clinic should be the next steps.
Literatur
1.
Zurück zum Zitat Harel R, Angelov L (2010) Spine metastases: current treatments and future directions. Eur J Cancer Oxf Engl 1990 46(15):2696–2707 Harel R, Angelov L (2010) Spine metastases: current treatments and future directions. Eur J Cancer Oxf Engl 1990 46(15):2696–2707
4.
Zurück zum Zitat Baker S, Fairchild A (2016) Radiation-induced esophagitis in lung cancer. Lung Cancer Auckl NZ 7:119–127 Baker S, Fairchild A (2016) Radiation-induced esophagitis in lung cancer. Lung Cancer Auckl NZ 7:119–127
6.
Zurück zum Zitat Byhardt RW, Scott C, Sause WT, Emami B, Komaki R, Fisher B, Lee JS, Lawton C (1998 Oct 1) Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 42(3):469–478. https://doi.org/10.1016/S0360-3016(98)00251-X CrossRefPubMed Byhardt RW, Scott C, Sause WT, Emami B, Komaki R, Fisher B, Lee JS, Lawton C (1998 Oct 1) Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 42(3):469–478. https://​doi.​org/​10.​1016/​S0360-3016(98)00251-X CrossRefPubMed
8.
Zurück zum Zitat Choy H, LaPorte K, Knill-Selby E, Mohr P, Shyr Y (1999 Apr) Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin Radiat Oncol 9(2 Suppl 1):90–96PubMed Choy H, LaPorte K, Knill-Selby E, Mohr P, Shyr Y (1999 Apr) Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin Radiat Oncol 9(2 Suppl 1):90–96PubMed
9.
Zurück zum Zitat Werner-Wasik M, Pequignot E, Leeper D, Hauck W, Curran W (2000 Oct 1) Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy. Int J Radiat Oncol Biol Phys 48(3):689–696. https://doi.org/10.1016/S0360-3016(00)00699-4 CrossRefPubMed Werner-Wasik M, Pequignot E, Leeper D, Hauck W, Curran W (2000 Oct 1) Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy. Int J Radiat Oncol Biol Phys 48(3):689–696. https://​doi.​org/​10.​1016/​S0360-3016(00)00699-4 CrossRefPubMed
20.
Zurück zum Zitat Cox BW, Spratt DE, Lovelock M, Bilsky MH, Lis E, Ryu S, Sheehan J, Gerszten PC, Chang E, Gibbs I, Soltys S, Sahgal A, Deasy J, Flickinger J, Quader M, Mindea S, Yamada Y (2012 Aug 1) International spine radiosurgery consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol 83(5):e597–e605. https://doi.org/10.1016/j.ijrobp.2012.03.009 CrossRef Cox BW, Spratt DE, Lovelock M, Bilsky MH, Lis E, Ryu S, Sheehan J, Gerszten PC, Chang E, Gibbs I, Soltys S, Sahgal A, Deasy J, Flickinger J, Quader M, Mindea S, Yamada Y (2012 Aug 1) International spine radiosurgery consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol 83(5):e597–e605. https://​doi.​org/​10.​1016/​j.​ijrobp.​2012.​03.​009 CrossRef
23.
Zurück zum Zitat Wijsman R, Dankers F, Troost EGC, Hoffmann AL, van der Heijden EHFM, de Geus-Oei L-F et al (2015 Oct) Multivariable normal-tissue complication modeling of acute esophageal toxicity in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-)radiotherapy. Radiother Oncol J Eur Soc Ther Radiol Oncol 117(1):49–54. https://doi.org/10.1016/j.radonc.2015.08.010 CrossRef Wijsman R, Dankers F, Troost EGC, Hoffmann AL, van der Heijden EHFM, de Geus-Oei L-F et al (2015 Oct) Multivariable normal-tissue complication modeling of acute esophageal toxicity in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-)radiotherapy. Radiother Oncol J Eur Soc Ther Radiol Oncol 117(1):49–54. https://​doi.​org/​10.​1016/​j.​radonc.​2015.​08.​010 CrossRef
24.
Zurück zum Zitat Dankers F, Wijsman R, Troost EGC, Monshouwer R, Bussink J, Hoffmann AL (2017 May 7) Esophageal wall dose-surface maps do not improve the predictive performance of a multivariable NTCP model for acute esophageal toxicity in advanced stage NSCLC patients treated with intensity-modulated (chemo-)radiotherapy. Phys Med Biol 62(9):3668–3681. https://doi.org/10.1088/1361-6560/aa5e9e CrossRefPubMed Dankers F, Wijsman R, Troost EGC, Monshouwer R, Bussink J, Hoffmann AL (2017 May 7) Esophageal wall dose-surface maps do not improve the predictive performance of a multivariable NTCP model for acute esophageal toxicity in advanced stage NSCLC patients treated with intensity-modulated (chemo-)radiotherapy. Phys Med Biol 62(9):3668–3681. https://​doi.​org/​10.​1088/​1361-6560/​aa5e9e CrossRefPubMed
27.
29.
Zurück zum Zitat Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, Raber-Durlacher JE, Sonis ST, Elad S, The Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) (2014 May 15) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120(10):1453–1461. https://doi.org/10.1002/cncr.28592 CrossRefPubMedPubMedCentral Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, Raber-Durlacher JE, Sonis ST, Elad S, The Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) (2014 May 15) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120(10):1453–1461. https://​doi.​org/​10.​1002/​cncr.​28592 CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Peterson DE, Bensadoun R-J, Roila F, ESMO Guidelines Working Group (2010) Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol Off J Eur Soc 21(Suppl 5):v261–v265CrossRef Peterson DE, Bensadoun R-J, Roila F, ESMO Guidelines Working Group (2010) Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol Off J Eur Soc 21(Suppl 5):v261–v265CrossRef
32.
Zurück zum Zitat Fogh SE, Deshmukh S, Berk LB, Dueck AC, Roof K, Yacoub S, Gergel T, Stephans K, Rimner A, DeNittis A, Pablo J, Rineer J, Williams TM, Bruner D (2017 Mar 15) A randomized phase 2 trial of prophylactic manuka honey for the reduction of chemoradiation therapy–induced esophagitis during the treatment of lung cancer: results of NRG oncology RTOG 1012. Int J Radiat Oncol 97(4):786–796. https://doi.org/10.1016/j.ijrobp.2016.11.022 CrossRef Fogh SE, Deshmukh S, Berk LB, Dueck AC, Roof K, Yacoub S, Gergel T, Stephans K, Rimner A, DeNittis A, Pablo J, Rineer J, Williams TM, Bruner D (2017 Mar 15) A randomized phase 2 trial of prophylactic manuka honey for the reduction of chemoradiation therapy–induced esophagitis during the treatment of lung cancer: results of NRG oncology RTOG 1012. Int J Radiat Oncol 97(4):786–796. https://​doi.​org/​10.​1016/​j.​ijrobp.​2016.​11.​022 CrossRef
Metadaten
Titel
Digestive toxicities after palliative three-dimensional conformal radiation therapy (3D-CRT) for cervico-thoracic spinal metastases
verfasst von
Guillaume Peyraga
Delphine Caron
Thibaut Lizee
Yann Metayer
Anne-Lise Septans
Yoann Pointreau
Fabrice Denis
Gerard Ganem
Cedrik Lafond
Sophie Roche
Olivier Dupuis
Publikationsdatum
23.12.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 6/2018
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-017-4001-4

Weitere Artikel der Ausgabe 6/2018

Supportive Care in Cancer 6/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.